Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I missed it too and only looked today thinking...maybe they will provide another Fortacin related update today. Certainly unusual if ever to have an op update two days in a row. Obviously Jamie is having an epiphany and suddenly realising there are indeed shareholders other than themselves.......LOL
thanks for pointing that out.id missed it.despite the no kidding,i actually thought you were joking about the name,but when i looked it up and showed it to mrs italian we both had hysterics.still at least he's not called "reason".joking apart.and despite it being as you rightly say,another mouth to feed i actually think it is potentially excellent news.ive always thought that jamie and mellon don't really have the right backgrounds for this type of product and area.(i know mellon is a bit of a jack of all trades ,but his style really is to launch the kites and see how they fly).if this chap has the right qualities and experience it could be just what they need.(will be looking into this a bit more this evening).whilst im inclined to regard the chinese update as more significant for the local market,this latest news may well have helped the s/p to build a little on the first news,albeit that we couldn't maintain the day's highs..not claiming this is a "deep"thought as i don't really do ratiocination,but its the best i can offer.
Any “deep” thoughts on whether todays rise was linked to that announcement ?
;-)
And another operational update yesterday for DLI, announcing yet another mouth to feed with the appointment of a CEO whose name is shortened to Deep (no kidding). I’m sure given the experience of ERP, they thought by employing a man with the name Deep will give good karma……not….lol.
Anyway, even though they state figures on a potential market, the company has still yet to make 1$.
Morning The.Italian,
Looks like yesterdays DVP rise has been totally wiped out today....... Onwards and downwards with that one....lol
afternoon bignose. i see DVP was up 6% today,although not suggesting it had any bearing on ERP,as it doesn't seem to register with investors.also of course,as we continue to sell down ,its movement becomes less meaningful.oh well,tomorrow is another day!
Morning The.Italian.
Yes, very strange why anyone would want to sell at this low with more positive news to come. I guess its all those caught in the last mini pump n dump. They are even probably selling at a loss.
Anyway, any rise today will be gone by tomorrow... :-)
looks like the update was pretty well received initially,but then the rise got sold into. volume up a bit,but still very small in value really.anyway,at least we have ended up a bit.(small mercies and all that).
evening all.just been looking over the update.very pleased to see it(and yes,a bit surprised in view of JG's previous comments).overall impression is pretty positive. don't want to draw unwarranted inferences,but i regard the speed of the china progress as very encouraging.seems like they want to crack on with it..it's still got a long way to go ,but encouraging. i was also pleased with the detail in the US info.yes,its taking an age,but at least things seem on track.i continue to feel a US deal is going to have to wait for fda approval, but provided we can cope with the financing need in the meantime,negotiating from a position of strength based on the actuality of FDA approval,rather than the hoped for expectation,is bound to result in a better deal.also pleased with the review of EU position.hope the reference to "royalty revenue"is not overly optimistic.would be good actually to get some! finally, is the reference to a possible japanese partner new? probably not, but i couldn't immediately recall it.i m probably just looking desperately for positives i expect.
Well, I am certainly surprised we eventually got one given It was alluded otherwise. Anyhoo. Certainly heading in the right direction. China is more advanced than I would have thought given the recent lockdowns, but I guess when money is no object things can be made to happen.
The EU appears to be making advances such that it will soon be on the shelves as OTC and of course with recommencement of production, certain Asian regions will be on sale too. It’s just unfortunate that the patent will run out at about the same time leaving poss only 1 to 2 years to make any decent money.
The US phase III has still not started which is a disappointment as is no mention specifically of the US deal, which I guess, but don’t understand why if there is so much positive data, is dependent on the phase III.
So from that, it certainly appears that 2023 may be the year of ERP. (Only 7 years after the EU launch and 9 years after the 2014 unambiguous way forward regarding the FDA approval process). Certainly makes one wonder what the A team have actually been doing all the time…..
Onwards and upwards at a slight incline ;-)